Seung Baek Hong1, Sang Hyun Choi2, Kyung Won Kim2, So Yeon Kim2, Jin Hee Kim2, Suk Kim1, Nam Kyung Lee1. 1. Department of Radiology, Biomedical Research Institute, Pusan National University Hospital, Pusan National University School of Medicine, Korea. 2. Department of Radiology and the Research Institute of Radiology, University of Ulsan College of Medicine, Asan Medical Center, Korea.
Abstract
BACKGROUND: Determining if a given patient with primary pancreatic adenocarcinoma (PDA) has hepatic metastasis is important for treatment planning. Several previous studies reported on the diagnostic performance of MRI for liver metastasis in patients with PDA. But the reported data are quite variable. PURPOSE: To systematically determine the diagnostic performance of MRI for liver metastasis in patients with PDA, including comparing it with computed tomography (CT). STUDY TYPE: Systemic review and meta-analysis. SUBJECTS: In all, 457 patients from five eligible articles. FIELD STRENGTH/SEQUENCE: Conventional MR sequences with or without contrast enhancement at 1.5T and 3T. ASSESSMENT: Two reviewers independently performed the data extraction. The reviewers identified and reviewed the original articles reporting the diagnostic performance of MRI for liver metastases in patients with PDA, including those articles making comparisons with CT. STATISTICAL TESTS: Meta-analytic summary sensitivity and specificity were calculated on a per-patient basis using a bivariate random effects model. We compared the meta-analytic summary sensitivity and specificity between MRI and CT. RESULTS: The meta-analytic summary sensitivity and specificity were 85% (95% confidence interval [CI], 74-92%; I2 = 0%) and 98% (95% CI, 78-100%; I2 = 85%), respectively. In comparison with CT, MRI showed a higher sensitivity (85% vs. 75%) but similar specificity (98% vs. 94%). DATA CONCLUSION: MRI had good overall diagnostic performance for liver metastasis in patients with PDA, with a higher sensitivity than CT. LEVEL OF EVIDENCE: 3 Technical Efficacy: Stage 2 J. Magn. Reson. Imaging 2020;51:1737-1744.
BACKGROUND: Determining if a given patient with primary pancreatic adenocarcinoma (PDA) has hepatic metastasis is important for treatment planning. Several previous studies reported on the diagnostic performance of MRI for liver metastasis in patients with PDA. But the reported data are quite variable. PURPOSE: To systematically determine the diagnostic performance of MRI for liver metastasis in patients with PDA, including comparing it with computed tomography (CT). STUDY TYPE: Systemic review and meta-analysis. SUBJECTS: In all, 457 patients from five eligible articles. FIELD STRENGTH/SEQUENCE: Conventional MR sequences with or without contrast enhancement at 1.5T and 3T. ASSESSMENT: Two reviewers independently performed the data extraction. The reviewers identified and reviewed the original articles reporting the diagnostic performance of MRI for liver metastases in patients with PDA, including those articles making comparisons with CT. STATISTICAL TESTS: Meta-analytic summary sensitivity and specificity were calculated on a per-patient basis using a bivariate random effects model. We compared the meta-analytic summary sensitivity and specificity between MRI and CT. RESULTS: The meta-analytic summary sensitivity and specificity were 85% (95% confidence interval [CI], 74-92%; I2 = 0%) and 98% (95% CI, 78-100%; I2 = 85%), respectively. In comparison with CT, MRI showed a higher sensitivity (85% vs. 75%) but similar specificity (98% vs. 94%). DATA CONCLUSION: MRI had good overall diagnostic performance for liver metastasis in patients with PDA, with a higher sensitivity than CT. LEVEL OF EVIDENCE: 3 Technical Efficacy: Stage 2 J. Magn. Reson. Imaging 2020;51:1737-1744.
Authors: G Litjens; D M Rivière; E J M van Geenen; S A Radema; L A A Brosens; M Prokop; C J H M van Laarhoven; J J Hermans Journal: BMC Cancer Date: 2020-08-10 Impact factor: 4.430